Interracial differences in prostate cancer progression among patients from the United States, China and Japan

Asian Journal of Andrology

Volumn 15, Issue 6, 2013, Pages 705-707

  Zhau, Haiyen E ^a   Li, Qinlong ^a   Chung, Leland W K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUANTUM DOT;

ARTICLE; CANCER GROWTH; CHINA; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC DIFFERENCE; GENOTYPE; HUMAN; JAPAN; PHENOTYPE; PROSTATE CANCER; RACE DIFFERENCE; UNITED STATES;

EID: 84887258079     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.86     Document Type: Article

References (31)

1. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer 2012; 118: 4280-9.
2. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ et al. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology 2007; 69: 1138-42. (Pubitemid 46891568)
3. Lopez DS, Peskoe SB, Joshu CE, Dobs A, Feinleib M et al. Racial/ethnic differences in serum sex steroid hormone concentrations in US adolescent males. Cancer Causes Control 2013; 24: 817-26.
4. Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 2006; 91: 4326-34. (Pubitemid 44833406)
5. Luo W, Birkett NJ, Ugnat AM, Mao Y. Cancer incidence patterns among Chinese immigrant populations in Alberta. J Immigr Health 2004; 6: 41-8.
6. Maskarinec G, Noh JJ. The effect of migration on cancer incidence among Japanese in Hawaii. Ethn Dis 2004; 14: 431-9. (Pubitemid 39140086)
7. Singh GK, Miller BA. Health, life expectancy, and mortality patterns among immigrant populations in the United States. Can J Public Health 2004; 95: I14-21. (Pubitemid 38967878)
8. Rowland GW, Schwartz GG, John EM, Ingles SA. Protective effects of low calcium intake and low calcium absorption vitamin D receptor genotype in the California Collaborative Prostate Cancer Study. Cancer Epidemiol Biomarkers Prev 2013; 22: 16-24.
9. Adkins RM, Krushkal J, Tylavsky FA, Thomas F. Racial differences in gene-specific DNA methylation levels are present at birth. Birth Defects Res A Clin Mol Teratol 2011; 91: 728-36.
10. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010; 16: 3539-47.
11. Chung LW, Ferland-Raymond G. Differences among rat sex accessory glands in their neonatal androgen dependency. Endocrinology 1975; 97: 145-53.
12. Chung LW, Chao H. Neonatal imprinting and hepatic cytochrome P-450. I. Comparison of testosterone hydroxylation in a reconstituted system between neonatally imprinted and nonimprinted rats. Mol Pharmacol 1980; 18: 543-9. (Pubitemid 11205386)
13. Tilghman SM. The sins of the fathers and mothers: genomic imprinting in mammalian development. Cell 1999; 96: 185-93. (Pubitemid 29059349)
14. Zeigler-Johnson CM, Spangler E, Jalloh M, Gueye SM, Rennert H et al. Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol 2008; 15: 3872-82.
15. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907.
16. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92.
17. Zhau HE, Zhao LS, Chung LW, Chen BQ, Troncoso P et al. Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1995; 1: 51-63.
18. Zhau HE, Zhao LS, Chen BQ, Kojima M. Interracial comparative study of prostate cancer in the United States, China, and Japan. Journal of cellular biochemistry. Supplement 1997; 28-29: 182-5.
19. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endo-thelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-90. (Pubitemid 30305085)
20. Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 2002; 189: 169-79. (Pubitemid 34229174)
21. Kuo YJ, Lin SF, Chang YH, Pan CC. Trends in prostate needle biopsy diagnosis. a ten year experience of a medical center in Taiwan. Pathol Int 2012; 62: 191-8.
22. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005; 41: 834-45. (Pubitemid 40467547)
23. Zhang J, Dhakal IB, Zhao Z, Li L. Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev 2012; 21: 480-9.
24. Mansur HS. Quantum dots and nanocomposites. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 2010; 2: 113-29.
25. Xing Y, Rao J. Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomarkers 2008; 4: 307-19.
26. Zrazhevskiy P, Gao X. Quantum dot imaging platform for single-cell molecular profiling. Nat Commun 2013; 4: 1619.
27. Alivisatos AP, Gu W, Larabell C. Quantum dots as cellular probes. Annu Rev Biomed Eng 2005; 7: 55-76. (Pubitemid 41170185)
28. Hotz CZ. Applications of quantum dots in biology: an overview. Methods Mol Biol 2005; 303: 1-17.
29. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4: 435-46. (Pubitemid 40774047)
30. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006; 66: 1664-73. (Pubitemid 44646357)
31. Hu P, Chu GC, Zhu G, Yang H, Luthringer D et al. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PloS ONE 2011; 6: e28670.